J.P. Morgan Notebook Day 3: Novartis' Cancer Reorg, AbbVie's Price Pledge, Genentech’s Partnering And More
Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco: Comments from President-elect Donald Trump hovered over the crowd, but companies aimed to stay focused on moving forward regardless of what policy changes are coming.
You may also be interested in...
Public Citizen reached out to the 28 largest biopharma manufacturers after Allergan announced its pricing pledge to see who else might follow suit. The answer was, not many.
Label-expansion plans for Imbruvica, along with approvals for Venclexta and Rova-T headline AbbVie's efforts to build a substantial cancer portfolio. The BTK inhibitor was AbbVie's second-best seller in 2016, passing HCV combo Viekira Pak.
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.